A Proteomic Dataset of HepG2 Cellular Responses to Cycloheximide-Induced Translational Arrest
Article Sidebar
Main Article Content
Abstract
Cycloheximide (CHX), a potent translational inhibitor, is widely used in cellular assays requiring translational blockade. Due to limited characterization of CHX-exposed cellular models, this study investigated the molecular and cellular effects of CHX in human hepatoma HepG2 cells. Cells were treated with various CHX concentrations for early (1 and 3 hours) and prolonged (18 and 24 hours) periods and evaluated for cellular responses. MTT assays showed no significant viability changes during early exposure, whereas prolonged treatment with 25 and 50 uM CHX reduced viability by approximately 30%. Sustained CHX exposure induced Sphase cell cycle arrest with minimal apoptosis (approximately 10%). LC-MS/MS analysis identified 19,482 differentially expressed proteins (DEPs), while PLS-DA revealed clear separation between untreated and CHX-treated HepG2 proteomes across time points. Volcano plot analysis identified the five most altered proteins at each time point, representing diverse cellular compartments and biological functions. STITCH network analysis further identified three interactome clusters associated with CHX responses: calcium-mediated survival signaling, xenobiotic detoxification, and ubiquitin-proteasome degradation. This characterized CHX-exposed HepG2 model provides a useful methodological reference for bioassays requiring translational stress.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Schneider-Poetsch T, Ju J, Eyler DE, Dang Y, Bhat S, Merrick WC, et al. Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin. Nat Chem Biol. 2010;6(3):209-17.
Kao SH, Wang WL, Chen CY, Chang YL, Wu YY, Wang YT, et al. Analysis of Protein Stability by the Cycloheximide Chase Assay. Bio Protoc. 2015;5(1).
Li J, Cai Z, Vaites LP, Shen N, Mitchell DC, Huttlin EL, et al. Proteome-wide mapping of short-lived proteins in human cells. Mol
Cell. 2021;81(22):4722-35 e5.
Ingolia NT, Ghaemmaghami S, Newman JR, Weissman JS. Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling. Science. 2009;324(5924):218-23.
Kreuz S, Siegmund D, Scheurich P, Wajant H. NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol. 2001;21(12):3964-73.
Ito K, Kiyosawa N, Kumagai K, Manabe S, Matsunuma N, Yamoto T. Molecular mechanism investigation of cycloheximideinduced hepatocyte apoptosis in rat livers by morphological and microarray analysis. Toxicology. 2006;219(1-3):175-86.
Vind AC, Wu Z, Firdaus MJ, Snieckute G, Toh GA, Jessen M, et al. The ribotoxic stress response drives acute inflammation, cell death, and epidermal thickening in UVirradiated skin in vivo. Mol Cell. 2024;84(24):4774-89 e9.
Arzumanian VA, Kiseleva OI, Poverennaya EV. The Curious Case of the HepG2 Cell Line: 40 Years of Expertise. Int J Mol Sci. 2021;22(23).
Li G, Qian Y, Chen Y, Cao M, Yang X, Kong D, et al. Wip1 contributes to the adaptation of HepG2 human liver cancer cells to stress hormone-induced DNA damage. Oncol Lett. 2023;25(1):31.
Bai J, Cederbaum AI. Cycloheximide protects HepG2 cells from serum withdrawal-induced apoptosis by decreasing p53 and phosphorylated p53 levels. J Pharmacol Exp Ther. 2006;319(3):1435-43.
Santiago-Lomeli M, Gomez-Quiroz LE, Ortiz-Ortega VM, Kershenobich D, Gutierrez-Ruiz MC. Differential effect of interleukin-10 on hepatocyte apoptosis. Life Sci. 2005;76(22):2569-79.
Chan C, Martin P, Liptrott NJ, Siccardi M, Almond L, Owen A. Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates. Pharmacol Res Perspect. 2017;5(5).
Kumar P, Nagarajan A, Uchil PD. Analysis of Cell Viability by the MTT Assay. Cold Spring Harb Protoc. 2018;2018(6).
Tarnathummanan C, Soimanee T, Khattiya J, Sretapunya W, Phaonakrop N, Roytrakul S, et al. Plasma proteomic profiles of patients with HIV infection and coinfection with hepatitis B/C virus undergoing anti‑retroviral therapy. Biomed Rep. 2024;21(5):155.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193(1):265-75.
Tyanova S, Temu T, Cox J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nat Protoc. 2016;11(12):2301-19.
Pang Z, Zhou G, Ewald J, Chang L, Hacariz O, Basu N, et al. Using MetaboAnalyst 5.0 for LC-HRMS spectra processing, multiomics integration and covariate adjustment of global metabolomics data. Nat Protoc. 2022;17(8):1735-61.
Leist M, Gantner F, Bohlinger I, Germann PG, Tiegs G, Wendel A. Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-alpha requires transcriptional arrest. J Immunol. 1994;153(4):1778-88.
Palczewski K, Sokal I, Baehr W. Guanylate cyclase-activating proteins: structure, function, and diversity. Biochem Biophys Res Commun. 2004;322(4):1123-30.
Yamaguchi M. The anti-apoptotic effect of regucalcin is mediated through multisignaling pathways. Apoptosis. 2013;18(10):1145-53.
Marques R, Maia CJ, Vaz C, Correia S, Socorro S. The diverse roles of calciumbinding protein regucalcin in cell biology: from tissue expression and signalling to disease. Cell Mol Life Sci. 2014;71(1):93-111.
Baxter RC. Signaling Pathways of the Insulin-like Growth Factor Binding Proteins. Endocr Rev. 2023;44(5):753-78.
Lariz FJ, Hernandez S, Bautista-Tovar DC, Houston KD. IGFBP-6 regulates breast cancer cell cycle progression by promoting exit out of G1. J Biol Chem. 2026;302(2):111069.
Pande M, Amos CI, Osterwisch DR, Chen J, Lynch PM, Broaddus R, et al. Genetic variation in genes for the xenobioticmetabolizing
enzymes CYP1A1, EPHX1, GSTM1, GSTT1, and GSTP1 and susceptibility to colorectal cancer in Lynch syndrome. Cancer Epidemiol Biomarkers Prev. 2008;17(9):2393-401.
Thum T, Erpenbeck VJ, Moeller J, Hohlfeld JM, Krug N, Borlak J. Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers. Environ Health Perspect. 2006;114(11):1655-61.
Walsh AA, Szklarz GD, Scott EE. Human cytochrome P450 1A1 structure and utility in understanding drug and xenobiotic metabolism. J Biol Chem. 2013;288(18):12932-43.
Bianchi M, Crinelli R, Giacomini E, Carloni E, Radici L, Scarpa ES, et al. A negative feedback mechanism links UBC gene expression to ubiquitin levels by affecting RNA splicing rather than transcription. Sci Rep. 2019;9(1):18556.
Kandel R, Jung J, Neal S. Proteotoxic stress and the ubiquitin proteasome system. Semin Cell Dev Biol. 2024;156:107-20.
Murai J, Tang SW, Leo E, Baechler SA, Redon CE, Zhang H, et al. SLFN11 Blocks Stressed Replication Forks Independently of ATR. Mol Cell. 2018;69(3):371-84 e6.
Hergeth SP, Schneider R. The H1 linker histones: multifunctional proteins beyond the nucleosomal core particle. EMBO Rep. 2015;16(11):1439-53.
Zhao W, Zhang Y, Lv T, He J, Zhu B. A case report of a novel HIST1H1E mutation and a review of the bibliography to evaluate the genotype-phenotype correlations. Mol Genet Genomic Med. 2023;11(12):e2273.
Morales-Camara S, Alexandre-Moreno S, Bonet-Fernandez JM, Atienzar-Aroca R, Aroca-Aguilar JD, Ferre-Fernandez JJ, et al. Role of GUCA1C in Primary Congenital Glaucoma and in the Retina: Functional Evaluation in Zebrafish. Genes (Basel). 2020;11(5).
Jo U, Murai Y, Chakka S, Chen L, Cheng K, Murai J, et al. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors. Proc Natl Acad Sci U S A. 2021;118(6).
Zoppoli G, Regairaz M, Leo E, Reinhold WC, Varma S, Ballestrero A, et al. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci U S A. 2012;109(37):15030-5.
Long X, Li Q, Zhi LJ, Li JM, Wang ZY. LINC00205 modulates the expression of EPHX1 through the inhibition of miR-184 in hepatocellular carcinoma as a ceRNA. J Cell Physiol. 2020;235(3):3013-21.
Gautheron J, Morisseau C, Chung WK, Zammouri J, Auclair M, Baujat G, et al. EPHX1 mutations cause a lipoatrophic diabetes syndrome due to impaired epoxide hydrolysis and increased cellular senescence. Elife. 2021;10.
Izquierdo-Bouldstridge A, Bustillos A, Bonet-Costa C, Aribau-Miralbes P, Garcia-Gomis D, Dabad M, et al. Histone H1 depletion triggers an interferon response in cancer cells via activation of heterochromatic repeats. Nucleic Acids Res. 2017;45(20):11622-42.
Kratzmeier M, Albig W, Meergans T, Doenecke D. Changes in the protein pattern of H1 histones associated with apoptotic DNA fragmentation. Biochem J. 1999;337 (Pt 2)(Pt 2):319-27.
